NNMT Inhibitor · Metabolic Weight-Loss · Protocol Guide
5-Amino-1MQ: The Honest NNMT Inhibitor Guide
5-Amino-1MQ is a small molecule that blocks the NNMT enzyme to raise cellular NAD+ and push fat cells back toward burning energy. The mechanism is well mapped and the animal data is consistent. The catch is the part the marketing skips: there is no published human trial. This guide draws that line clearly.
- FDA Status
- Investigational, 503A Compounded
- Pharmacy
- Optimal Balance Pharmacy (503A licensed)
- Medical Service
- RxPepsDirect, physician-supervised
- Access
- 28 U.S. States
Our promise: The human evidence for 5-Amino-1MQ is, as of this writing, zero published controlled trials. Everything we know about weight loss with this molecule comes from cell culture and diet-induced-obese mice. We say that plainly instead of dressing animal data up as proof.
Medically reviewed by Dr. Jonathan Snipes, MD. Last reviewed June 8, 2026.On this page
Section 01
What 5-Amino-1MQ Actually Is
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small molecule, not a peptide, even though it is sold and prescribed alongside metabolic peptides. It was designed to do one specific thing: block an enzyme called nicotinamide N-methyltransferase, usually shortened to NNMT. NNMT is normal and useful in the right amount, but in the fat tissue and liver of obese animals it is overexpressed, and that excess is tied to a slowed, fat-storing metabolic state.
The idea behind 5-Amino-1MQ is to turn that excess enzyme activity down. When NNMT is inhibited, two cellular currencies it normally spends, NAD+ and SAM, are conserved and rise inside the cell. Higher NAD+ supports the energy-burning side of metabolism, and the result, in animal models, is fat cells that store less and burn more. The molecule grew out of academic work showing that simply knocking down the NNMT gene in mice protected them from gaining weight on a high-fat diet.
What 5-Amino-1MQ is not is just as important. It is not a GLP-1 and does not suppress appetite. It is not a stimulant. It is not a hormone. And it is not, by any honest reading of the literature, a proven human weight-loss drug. It is a mechanistically promising compound whose human story has not been written yet.
NNMT
The enzyme 5-Amino-1MQ inhibits, overexpressed in obese fat tissue
2014
Year NNMT knockdown was first shown to protect mice from diet-induced obesity (Nature)
0
Published human clinical trials for weight loss to date
503A
Pathway for U.S. compounded access under physician prescription
Section 02
Who It Is Actually For
Because there is no human trial, every row in this table is an inference from mechanism and animal data, not a tested human indication. The honest framing matters here more than usual: a good fit means the rationale is plausible, not that the result is proven.
| Profile | Primary Motivation | Evidence Basis | Fit |
|---|---|---|---|
| Metabolic Slowdown, Plateaued Fat Loss | Restore cellular energy metabolism alongside diet and activity | The mouse studies targeted exactly this state. Plausible, not human-proven. | Best Rationale |
| Adjunct to a Calorie-Controlled Diet | Add a metabolic lever to a diet that is already working | A mouse study paired NNMT inhibition with a reduced-calorie diet for an additive effect. | Mechanistic Fit |
| Part of a Broader Recomp Stack | A different pathway to pair with lipolytic or GH-axis peptides | Mechanistically independent of GLP-1, GHRH, and lipolytic peptides. | Exploratory |
| Looking for Appetite Suppression | Eat less, feel full | Wrong tool. In mice, NNMT inhibition did not reduce food intake. | Poor Fit |
| Pregnant, Nursing, or Planning Pregnancy | Any goal | No safety data. Hard contraindication. | Do Not Use |
Profile
Primary Motivation
Evidence Basis
Fit
Profile
Primary Motivation
Evidence Basis
Fit
Profile
Primary Motivation
Evidence Basis
Fit
Profile
Primary Motivation
Evidence Basis
Fit
Profile
Primary Motivation
Evidence Basis
Fit
Section 03
How 5-Amino-1MQ Works
The mechanism is the strongest part of the 5-Amino-1MQ story, and it is worth understanding because it explains both the promise and why you should not expect a felt effect. Everything here is established biochemistry and animal pharmacology, not human outcome data.
NNMT Enzyme Inhibition
5-Amino-1MQ binds and inhibits NNMT, an enzyme that is overexpressed in obese adipose tissue. The methylquinolinium scaffold is membrane-permeable and selective, meaning it crosses into the cell and does not broadly inhibit related methyltransferases.
NAD+ and SAM Conservation
Because NNMT normally spends nicotinamide and SAM, inhibiting it raises intracellular NAD+ and SAM. Higher NAD+ supports the energy-burning machinery of the cell, including SIRT1 signaling, in the animal models.
Less Storage, More Burn
In cultured adipocytes, NNMT inhibitors suppressed lipogenesis, the fat-storage program. In mice, treatment increased energy expenditure and reduced fat mass and adipocyte size without cutting food intake.
No Appetite Effect
Notably, the mouse studies reported no change in total food intake. The fat loss came from how the body used and stored energy, not from eating less. This is the opposite of an appetite-suppressant mechanism.
Section 04
What the Evidence Shows
This is the section that matters most, because with 5-Amino-1MQ the gap between mechanism and human proof is total: the mechanism is well supported, and the human proof does not exist. Here is the actual record, in order, according to PubMed.
| Study | Design | Key Finding | Strength |
|---|---|---|---|
| Kraus 2014 (Nature) [1] | Genetic knockdown, mice | Knocking down NNMT in fat and liver protected mice from diet-induced obesity by increasing energy expenditure. Established NNMT as a metabolic target. | Foundational, Animal |
| Neelakantan 2018 (Biochem Pharmacol) [2] | Small-molecule inhibitor, cells + DIO mice | A potent methylquinolinium NNMT inhibitor reduced body weight and white fat mass and lowered cholesterol in high-fat-diet mice, without changing food intake or causing observed adverse effects. | Key Preclinical |
| Sampson 2021 (Sci Rep) [3] | Inhibitor + reduced-calorie diet, DIO mice | NNMT inhibition combined with a lean-diet substitution normalized body composition and liver fat beyond diet alone. | Combination, Animal |
| Babula 2024 (Diabetes Obes Metab) [4] | 5A1MQ, 28-day DIO mouse study + PK | Once-daily 5A1MQ dose-dependently limited weight and fat gain, improved glucose tolerance and insulin sensitivity, and reduced liver fat. Good tissue distribution after subcutaneous dosing. | Most Direct, Animal |
| Ehebauer 2020 (Life Sci) [5] | Mechanistic, cultured adipocytes | Showed how glucose availability and the mTOR pathway regulate NNMT expression in fat cells, supporting NNMT's role in metabolic state. | Mechanistic, In Vitro |
Study
Design
Key Finding
Strength
Study
Design
Key Finding
Strength
Study
Design
Key Finding
Strength
Study
Design
Key Finding
Strength
Study
Design
Key Finding
Strength
Section 05
Realistic Expectations
5-Amino-1MQ is a slow, quiet, metabolic compound with no day-one effect to chase. The timeline below is an honest projection from the mechanism and the animal data, not a promise. Because there is no human trial, your individual response is genuinely unpredictable.
No Felt Effect
Expect to feel nothing. 5-Amino-1MQ acts on a metabolic enzyme, not on appetite or stimulant pathways. The absence of an early sensation is normal and tells you nothing about whether the compound is doing anything.
Metabolic Adjustment
If 5-Amino-1MQ is going to help, this is the window where a metabolic shift would begin to support an already-working diet and activity plan. Any scale movement here is small and depends heavily on the rest of your protocol.
Body Composition Window
The animal fat-loss effects accumulated over weeks of daily dosing, not all at once. This is the realistic window to look for a change in body composition, measured against a steady diet so you can tell signal from noise.
Reassess With Your Prescriber
A single course is typically reviewed here. With no human data on long-term use, your prescriber decides whether to cycle, extend, or stop based on your measured results and tolerance.
Section 06
Dosing Protocol
There is no human dosing study, so the protocol below is clinical practice extrapolated from the animal and pharmacokinetic work, not a trial-validated regimen. Your RxPepsDirect physician sets and adjusts the dose for you.
| Context | Dose | Route / Frequency | Evidence Basis |
|---|---|---|---|
| Babula 2024 Mouse Study | Weight-based, once daily | Subcutaneous, daily, 28 days (mice) | Animal, Not Human |
| RxPepsDirect Standard | 1 mg (20 units) | Subcutaneous, daily, 8 to 12 weeks | Clinical Practice |
| Cycling Option | Same dose | May be cycled or extended per prescriber | Physician Decision |
| Exceeding the Prescribed Dose | Higher than labeled | Not supported | No Human Safety Data |
Context
Dose
Route / Frequency
Evidence Basis
Context
Dose
Route / Frequency
Evidence Basis
Context
Dose
Route / Frequency
Evidence Basis
Context
Dose
Route / Frequency
Evidence Basis
Subcutaneous injection into abdominal fat with a standard insulin syringe. Twenty units on the syringe equals 1 mg at the 5 mg/mL concentration Optimal Balance Pharmacy ships. Rotate sites day to day. Timing is flexible because 5-Amino-1MQ does not align with any hormonal pulse, though most patients dose at a consistent time for routine. Pair the protocol with a calorie-aware diet and activity: the animal data is clearest when the compound supports a diet rather than substitutes for one.
Section 07
Ready to Inject
0
Reconstitution steps required
503A
Licensed pharmacy (Optimal Balance), physician-supervised
Overnight
FedEx shipping in a reusable cooled travel case
Section 08
Safety and Side Effects
In the animal studies, NNMT inhibitors were reported without observed adverse effects at the doses tested, and food intake was unchanged. That is reassuring as far as it goes, but it goes only as far as a mouse. There is no published human safety record, which is the central caution for this molecule.
| Consideration | Detail | Action |
|---|---|---|
| Injection site reaction | Mild local redness or soreness is the most likely event | Rotate sites. Let the vial warm slightly before injecting. |
| No human safety data | Long-term human effects of NNMT inhibition are uncharacterized | Treat this as an investigational compound and stay in physician follow-up. |
| Metabolic medications | 5-Amino-1MQ alters cellular energy metabolism | Tell your prescriber about any diabetes or metabolic medication before starting. |
| Pregnancy / lactation | No safety data | Avoid. |
Consideration
Detail
Action
Consideration
Detail
Action
Consideration
Detail
Action
Consideration
Detail
Action
Section 09
Stacking
Pairs Well With
AOD-9604
Direct lipolysis through a separate pathway. Pairs a fat-breakdown signal with the NNMT metabolic lever. Independent timing, no conflict.
NAD+ Injection
Complementary logic: 5-Amino-1MQ conserves cellular NAD+ by blocking NNMT, while NAD+ dosing supplies the precursor pool. Coordinate with your prescriber.
Calorie-aware diet and activity
Not a compound, but the most evidence-aligned pairing. The animal data is strongest when NNMT inhibition supports a controlled diet.
Avoid or Use Caution
Stacking to replace diet
No mechanism here overrides a poor diet, even in mice. Layering compounds to avoid dietary change is not supported by the evidence.
Pregnancy / lactation
No safety data. Avoid.
Section 10
Pricing
Pharmacy: Medication
$80 per 25 mg vial. Compounded and shipped by Optimal Balance Pharmacy, a 503A licensed compounding pharmacy. Pre-reconstituted at 5 mg/mL, FedEx overnight.
Medical Service: Physician Consultation
$39 medical visit fee. Intake consultation including history review, protocol design, prescription writing, and follow-up. Billed by RxPepsDirect for the medical service only.
Section 11
Legal Access in 28 States
503A Licensed Pharmacy
Optimal Balance Pharmacy, U.S. licensed
Physician Prescription Required
Compounded medication, Rx only
Investigational Compound
Preclinical evidence, no FDA approval
Off-Label, Legal Practice
Standard and legal in U.S. medicine
5-Amino-1MQ is an investigational compound. It has not been approved by the FDA for any indication, and it has not reached human trials for weight loss. In the United States it is available through 503A patient-specific compounding under a physician prescription. The 503A pathway is the documented legal route for compounded access. RxPepsDirect prescribers serve patients in 28 states.
Section 12
Community Q&A
Is there any human trial showing 5-Amino-1MQ causes weight loss?
No. As of this writing there is no published, peer-reviewed human clinical trial of 5-Amino-1MQ, or of any NNMT inhibitor, for weight loss. The entire weight-loss case rests on cell culture and diet-induced-obese mouse studies. The mechanism is well characterized and the animal results are consistent, but the jump from mouse to human is the step that has not been tested.
What does it actually do at the cellular level?
It inhibits NNMT, an enzyme overexpressed in the fat tissue of obese animals. Blocking NNMT raises intracellular NAD+ and SAM, suppresses fat storage, and in mice increases energy expenditure and reduces fat mass without changing how much the animals ate.
Will I feel anything?
Probably not directly. 5-Amino-1MQ works on a metabolic enzyme, not on appetite or stimulant receptors. There is no acute felt effect. Any benefit shows up as a gradual change in body composition over weeks alongside diet, not as a sensation after a dose.
Is it even a peptide?
No, technically it is a small molecule, a methylquinolinium compound, not a peptide. It is grouped with metabolic peptides because it is compounded and prescribed through the same 503A pathway for the same fat-loss goal. The chemistry differs, but the prescribing and dispensing do not.
How long is a course?
RxPepsDirect courses generally run 8 to 12 weeks, with your prescriber reassessing before any extension or repeat. Because there is no human long-term data, that review matters.
Section 13
The RxPepsDirect Model
Pharmacy: Optimal Balance, 503A Licensed
Optimal Balance Pharmacy compounds your 5-Amino-1MQ under a patient-specific prescription, USP <797> sterile standards, and federal 503A oversight.
Medical Service: RxPepsDirect Physicians
A licensed physician reviews your history, screens for contraindications, designs your protocol, and writes your prescription. RxPepsDirect bills the $39 medical visit fee for this service.
Transparent Safety Communication
This guide flags that there is no human trial, that all the weight evidence is from mice and cell culture, that there is no FDA approval, and that the dosing is extrapolated, not validated. We do not hide limitations to make a sale.
Legal Access in 28 States
Every shipment is a compounded prescription medication filled by a 503A licensed pharmacy under a physician prescription.
References
- Kraus D, Yang Q, Kong D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014. PMID: 24717514
- Neelakantan H, Vance V, Wetzel MD, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol. 2018. PMID: 29155147
- Sampson CM, Dimet AL, Neelakantan H, et al. Combined nicotinamide N-methyltransferase inhibition and reduced-calorie diet normalizes body composition and enhances metabolic benefits in obese mice. Sci Rep. 2021. PMID: 33707534
- Babula JJ, Bui D, Stevenson HL, et al. Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction. Diabetes Obes Metab. 2024. PMID: 39161060
- Ehebauer F, Ghavampour S, Kraus D. Glucose availability regulates nicotinamide N-methyltransferase expression in adipocytes. Life Sci. 2020. PMID: 32112869
Related protocol guides
Other protocols in the same clinical territory. Each guide is co-bylined by a licensed RxPepsDirect prescriber.
GLP-1 protocol guide
Microdose GLP-1: dosing math, evidence, and how to start safely in 2026
Microdosing semaglutide or tirzepatide means running them below the FDA-approved starter dose. The vial-duration math, the published evidence, and how to start with a provider.
Growth hormone fragment fat-loss protocol
AOD-9604 (GH fragment 176-191) protocol guide: the lipolysis mechanism, the failed obesity trial, and the honest fat-loss picture
A growth hormone fragment built to burn fat without raising IGF-1. The rodent data is real, but the pivotal 534-subject obesity trial did not beat placebo and development stopped in 2007. Honest about the gap.
Triple monoamine reuptake inhibitor (weight loss)
Tesofensine protocol guide: triple monoamine mechanism, Phase IIb data, and the cardiovascular signal
Not a peptide despite frequent miscategorization. 9.2 percent Phase IIb weight loss. Real cardiovascular signal. Monitoring is not optional.
Continue reading